Clinical Trial Update: Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update evaluating evolocumab in high cardiovascular risk patients without prior myocardial infarction or stroke (primary prevention) with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Heart Disease

Drugs mentioned

• Repatha (Evolocumab)

Snippet

Sponsor: Amgen | Conditions: Coronary Heart Disease (CHD) | Phase 3 | Status: COMPLETED